ERBB2 and neoplasm: Furthermore, in vivo biodistribution and tumor localization data using a HER2-expressingSKOV3 xenograft mouse model indicated efficient tumor targeting andretention for up to 10 days postinjection of the TZM-E/K-CF750 conjugate.